Q-omics provides the consensus-scored DHRS4L2 profile across patient tissues and cancer cell-line models. DHRS4L2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, DHRS4L2 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, DHRS4L2 RNA expression shows 17,967 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight OV, KIRP, and THYM as cancer lineages where DHRS4L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DHRS4L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DHRS4L2 survival associations across molecular data types. DHRS4L2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DHRS4L2 RNA expression–survival associations across cancer types. High DHRS4L2 expression shows unfavorable associations in KICH, ACC and UCS, but favorable associations in OV, BRCA and LUSC. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify OV as the clearest survival context for DHRS4L2 RNA expression.
This table summarizes DHRS4L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for DHRS4L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DHRS4L2 shows lower tumor expression in KIRP, COAD, KIRC, LUAD, THCA and CHOL. The KIRP box plot shows higher DHRS4L2 RNA expression in normal versus tumor tissue (log2 FC = −0.939, t-test p < 0.001).
This table shows molecular features associated with DHRS4L2 in patient tissues and cancer cell lines. In patient samples, DHRS4L2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DHRS4L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
